65,437 trials
Hypercholesterolemia
Primary: Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Cognitive Domain Spatial Working Memory (SWM) Strategy Z-Score at Week 96 — -0.180…
Breast Cancer · Neutropenia
Primary: Duration in Days of Grade 4 Neutropenia in Chemotherapy Cycle 1 — 0.2; 0.2 days
Lymphoma, Non-Hodgkin · Lymphoma, B-Cell · Chronic Lymphocytic Leukemia
Primary: Number of Adverse Events After CAR 20/19-T Cell Infusion — 7; 4; 22 Serious Adverse Events
Ease of Use
Primary: Percentage of Nights' Data That Were Successfully Recorded — 79; 86; 100 percentage of nights' data
Cancer, Breast · Inflammation
Primary: Number of Participants Per Cutaneous Toxicity Grade (0, 1, 2, 3, 4) — 60; 11; 0; 0 Participants
Anemia; Hemodialysis Dependent Chronic Kidney Disease
Primary: Mean Hb Level of Week 20 and Week 24 — 10.75 g/dL
Pelvic Adhesions
Primary: Number of Participants in Which Adhesions Were Prevented. — 15; 5; 4; 3 Participants
Follicular Lymphoma · Marginal Zone B-Cell Lymphoma · MALT Lymphoma
Primary: Response Rate to Lenalidomide-dexamethasone + Rituximab Therapy in Relapsed Small B-cell Lymphoma With Rituximab Resistance — 14; 13 Participants
Pancreatic Cancer
Primary: Determine the Maximum Tolerated Dose of Gemcitabine to be Delivered Locally to the Pancreas — 1000 mg/m^2
Trauma to the Spleen
Primary: Number of Participants Who Were Enrolled Within 18 Months of Study Initiation — 23; 23 Participants
Type2 Diabetes Mellitus
Primary: Cmax (Maximum Observed Plasma Concentration) — 90.8; 96.5; 6.0; 6.6 ng/mL
Pulmonary Disease, Chronic Obstructive
Primary: Part A: RPL554 Plasma Pharmacokinetic Parameter (AUC0-12) — 260; 472; 2210; 4160 h*pg/mL
Metastatic Malignant Neoplasm in the Lung · Metastatic Osteosarcoma · Recurrent Osteosarcoma
Primary: Disease Control — 11 Participants
Treatment Resistant Depression
Primary: Percentage Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Score From Pre-treatment to 1-month Post-treatment. — -53; -11 percent change in MADRS score…
AL Amyloidosis
Primary: Assess the Number of Patients Who Respond to Treatment — 5; 13; 2; 1 Participants